InvestorsHub Logo
Followers 28
Posts 1440
Boards Moderated 0
Alias Born 12/18/2014

Re: survivor1x post# 441473

Saturday, 02/05/2022 4:01:01 AM

Saturday, February 05, 2022 4:01:01 AM

Post# of 698717
Agree with you response. Additionally: Also in the hope to have a one size fits all streamlined manufacturing approach which would suit BP more comfortably. There is trepidation (and there should be) in pivoting to personalized autologous produced therapies as its not their (BP) strong suit.

"There is a reason why the likes of BNTX/RHHBY, GRTS, GNCA and MRNA/MRK are selecting which neoantigens to target with their vaccines."

Because they think they are smarter than the immune system that has evolved over eons to pick up the perfect antigen set per patient per tumor. - I mean if you could match patients to multiple antigens and then follow back up with new antigens once those are down regulated. Seems like a lot of work instead of working with nature


Recovering former moderator.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News